Overview

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Status:
Active, not recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue.

Phase:

Phase 2

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborators:

National Cancer Institute (NCI)
Viewray Inc.

Treatments:

Androgen Antagonists
Androgens
Ascorbic Acid
Estrogens, Conjugated (USP)
Hormone Antagonists
Hormones
Methyltestosterone
Prolactin Release-Inhibiting Factors